In a phase II clinical trial, 21 treatment-naïve metastatic NSCLC patients with tumor PD-L1 ≥50% were treated with pembrolizumab and delayed itacitinib (a JAK1 inhibitor) (151). This evidence concerns the gene CD274 and non-small cell lung carcinoma.